Endo International (ENDP) Issues FY18 Earnings Guidance

Share on StockTwits

Endo International (NASDAQ:ENDP) (TSE:ENL) issued an update on its FY18 earnings guidance on Thursday morning. The company provided EPS guidance of $2.65-2.75 for the period, compared to the Thomson Reuters consensus EPS estimate of $2.60. The company issued revenue guidance of $2.87-2.92 billion, compared to the consensus revenue estimate of $2.81 billion.Endo International also updated its FY 2018 guidance to $2.65-2.75 EPS.

Shares of NASDAQ:ENDP opened at $13.49 on Friday. The stock has a market cap of $3.59 billion, a P/E ratio of 3.51, a PEG ratio of 1.54 and a beta of 0.65. Endo International has a 12 month low of $5.27 and a 12 month high of $18.50.

Endo International (NASDAQ:ENDP) (TSE:ENL) last issued its quarterly earnings results on Thursday, November 8th. The company reported $0.71 EPS for the quarter, beating the consensus estimate of $0.59 by $0.12. The company had revenue of $745.00 million for the quarter, compared to the consensus estimate of $694.93 million. Endo International had a negative net margin of 34.72% and a positive return on equity of 237.45%. The firm’s revenue was down 5.3% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.91 EPS. On average, equities analysts predict that Endo International will post 2.68 earnings per share for the current fiscal year.

Several equities analysts recently commented on ENDP shares. Deutsche Bank set a $11.00 price target on shares of Endo International and gave the company a buy rating in a report on Wednesday, July 18th. Zacks Investment Research upgraded shares of Endo International from a hold rating to a buy rating and set a $18.00 price target on the stock in a report on Monday, September 24th. Goldman Sachs Group upgraded shares of Endo International from a sell rating to a neutral rating and upped their price target for the company from $14.00 to $15.00 in a report on Tuesday, September 11th. Cantor Fitzgerald upped their price target on shares of Endo International from $12.00 to $18.00 and gave the company a neutral rating in a report on Friday, October 19th. Finally, ValuEngine downgraded shares of Endo International from a buy rating to a hold rating in a report on Tuesday, September 4th. One analyst has rated the stock with a sell rating, fourteen have assigned a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the company. The stock has a consensus rating of Hold and a consensus target price of $14.97.

In other Endo International news, Director Roger H. Kimmel sold 26,074 shares of the business’s stock in a transaction dated Tuesday, August 14th. The shares were sold at an average price of $15.90, for a total value of $414,576.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 0.80% of the stock is owned by insiders.

ILLEGAL ACTIVITY WARNING: This report was published by Week Herald and is the sole property of of Week Herald. If you are viewing this report on another publication, it was copied illegally and reposted in violation of international copyright & trademark legislation. The original version of this report can be read at https://weekherald.com/2018/11/10/endo-international-endp-issues-fy18-earnings-guidance.html.

About Endo International

Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States, Canada, and internationally. The company operates through three segments: U.S. Generic Pharmaceuticals, U.S. Branded Pharmaceuticals, and International Pharmaceuticals.

Read More: Why is Cost of Capital Important?

Earnings History and Estimates for Endo International (NASDAQ:ENDP)

Receive News & Ratings for Endo International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply